Barclays initiated coverage on T. Rowe Price with a new price target
$TROW
Investment Bankers/Brokers/Service
Finance
Barclays initiated coverage of T. Rowe Price with a rating of Underweight and set a new price target of $99.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/3/2025 | $108.00 | Market Perform | BMO Capital Markets |
| 9/12/2024 | $109.00 | Equal Weight | Wells Fargo |
| 8/27/2024 | $99.00 | Underweight | Barclays |
| 4/11/2024 | $106.00 → $120.00 | Underperform → Mkt Perform | Keefe Bruyette |
| 4/8/2024 | $92.00 → $114.00 | Sell → Hold | TD Cowen |
| 1/8/2024 | $95.00 → $105.00 | Equal Weight → Underweight | Wells Fargo |
| 1/4/2024 | $88.00 | Underperform | TD Cowen |
| 10/31/2023 | $100.00 → $95.00 | Sell → Neutral | Citigroup |
4 - PRICE T ROWE GROUP INC (0001113169) (Issuer)
4 - PRICE T ROWE GROUP INC (0001113169) (Issuer)
3 - PRICE T ROWE GROUP INC (0001113169) (Issuer)
BMO Capital Markets initiated coverage of T. Rowe Price with a rating of Market Perform and set a new price target of $108.00
Wells Fargo initiated coverage of T. Rowe Price with a rating of Equal Weight and set a new price target of $109.00
Barclays initiated coverage of T. Rowe Price with a rating of Underweight and set a new price target of $99.00
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as
The T. Rowe Price Short Municipal Income, Long Municipal Income, High Income Municipal and Multi-Sector Income ETFs began trading today, expanding the firm's ETF lineup to 28 BALTIMORE, Nov. 20, 2025 /PRNewswire/ -- T. Rowe Price (NASDAQ-GS: TROW), a global investment management firm and leader in retirement, announced today the addition of four new active fixed income exchange-traded funds (ETF): T. Rowe Price Short Municipal Income ETF (Ticker: TMNS), T. Rowe Price Long Municipal Income ETF (Ticker: TMNL), T. Rowe Price High Income Municipal ETF (Ticker: THYM), and the T. Rowe Price Multi-Sector Income ETF (Ticker: TMSF). The new funds began trading on the NASDAQ exchange today. T. Rowe Pr
Though inflation and high valuations remain a concern, the AI boom combined with monetary and fiscal stimulus in the U.S. and an expansionary phase in Europe appears to set the stage for favorable market conditions in 2026. BALTIMORE, Nov. 19, 2025 /PRNewswire/ -- T. Rowe Price held its 43rd annual global market outlook press briefing today, featuring a panel of the firm's investment experts sharing their forecasts for the 2026 global financial markets. Speakers included Tim Murray, capital markets strategist; Josh Nelson, head of Global Equity; Ken Orchard, head of International Fixed Income; Sébastien Page, head of Global Multi-Asset and chief investment officer; and Glenn August, founder
8-K - PRICE T ROWE GROUP INC (0001113169) (Filer)
10-Q - PRICE T ROWE GROUP INC (0001113169) (Filer)
8-K - PRICE T ROWE GROUP INC (0001113169) (Filer)
BALTIMORE, Oct. 31, 2025 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW) announced its financial results for the third quarter of 2025. The earnings release can be found on the firm's website at troweprice.com/newsroom. Chair, Chief Executive Officer, and President Rob Sharps and Chief Financial Officer Jen Dardis will provide an update on business performance, review financial results, and answer questions on a webcast today from 8:00 - 8:45 AM ET. To access the webcast or to obtain dial-in instructions to ask a question, please visit investors.troweprice.com. Sup
BALTIMORE, Oct. 28, 2025 /PRNewswire/ -- T. Rowe Price Group (NASDAQ-GS: TROW), a global asset management firm and a leader in retirement, announced today that its Board of Directors has declared a quarterly dividend of $1.27 per share payable on December 30, 2025, to stockholders of record as of the close of business on December 15, 2025. ABOUT T. ROWE PRICE T. Rowe Price (NASDAQ-GS: TROW) is a leading global asset management firm entrusted with managing $1.77 trillion in client assets as of September 30, 2025, about two-thirds of which are retirement-related. Renowned for ov
BALTIMORE, Nov. 1, 2024 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW), announced today that its Board of Directors has declared a quarterly dividend of $1.24 per share payable December 27, 2024, to stockholders of record as of the close of business on December 13, 2024. ABOUT T. ROWE PRICEFounded in 1937, T. Rowe Price (NASDAQ – GS: TROW) helps individuals and institutions around the world achieve their long-term investment goals. As a large global asset management company known for investment excellence, retirement leadership, and independent proprietary research, the firm is built on a culture of integrity that puts client interests first. Clients rely on the award-winning f
SC 13G/A - PRICE T ROWE GROUP INC (0001113169) (Subject)
SC 13G/A - PRICE T ROWE GROUP INC (0001113169) (Subject)
SC 13G/A - PRICE T ROWE GROUP INC (0001113169) (Subject)
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as
BALTIMORE, Nov. 13, 2025 /PRNewswire/ -- T. Rowe Price announced today the creation of a Global Strategy function to drive its strategic vision and elevate long-term planning. Andrew Reich will join the firm as head of Global Strategy on January 5, 2026. In this role, Reich will oversee the firm's corporate strategy, corporate development, mergers and acquisitions, and product development. Reich brings deep industry expertise, having most recently served as a partner and head of the Asset Management Practice for North America at McKinsey & Company. During his tenure, he helped
BALTIMORE, May 9, 2025 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW), announced today that its Board of Directors has declared a quarterly dividend of $1.27 per share payable June 27, 2025, to stockholders of record as of the close of business on June 13, 2025. Additionally, at its annual meeting yesterday, T. Rowe Price Group, Inc.'s stockholders: Elected 11 directors to its Board of Directors;Approved, by a nonbinding advisory vote, the compensation paid by the Company to its Named Executive Officers;Ratified the appointment of KPMG LLP as the Company's indepen